carfilzomib

carfilzomib

(car- fil-zoe- mib) ,

Kyprolis

(trade name)

Classification

Therapeutic: antineoplastics
Pharmacologic: proteasome inhibitors
Pregnancy Category: D

Indications

Treatment of multiple myeloma in patients whose disease has progressed despite previous therapy with bortezomib and immunotherapy in the previous 60 days.

Action

Acts as a proteasome inhibitor by binding to sites on the 20s proteasome. Has antiproliferative and proapoptotic activity.

Therapeutic effects

Delayed progression of multiple myeloma.

Pharmacokinetics

Absorption: IV administration results in complete bioavailability.
Distribution: Unknown.
Metabolism and Excretion: Rapidly and extensively metabolized by extrahepatic enzymes. Metabolites have no antineoplastic activity.
Half-life: Unknown.

Time/action profile (proteasome inhibition)

ROUTEONSETPEAKDURATION
IVwithin 1 hrunknown>48 hr

Contraindications/Precautions

Contraindicated in: Obstetric: Pregnancy (may cause fetal harm); Lactation: Breast feeding should be avoided.
Use Cautiously in: History of cardiovascular disease (may ↑ risk of adverse cardiovascular reactions, safe and effective use in patients with New York Heart Association Class III and IV heart failure has not been established); Large tumor load (↑ risk of tumor lysis syndrome); Dehydration, diarrhea or electrolyte abnormalities (correct prior to treatment); Hepatic impairment (safe and effective use has not been established); End stage renal disease (dose should be administered following dialysis); Pediatric: Safe and effective use in children has not been established.

Adverse Reactions/Side Effects

Central nervous system

  • dizziness (most frequent)
  • fatigue (most frequent)
  • headache (most frequent)
  • insomnia (most frequent)
  • weakness (most frequent)

Respiratory

  • cough (most frequent)
  • dyspnea (most frequent)

Cardiovascular

  • heart failure (life-threatening)
  • hypertension (most frequent)
  • myocardial ischemia (life-threatening)
  • peripheral edema (most frequent)
  • pulmonary hypertension

Gastrointestinal

  • hepatic failure (life-threatening)
  • anorexia (most frequent)
  • constipation (most frequent)
  • diarrhea (most frequent)
  • hepatic toxicity
  • nausea

Genitourinary

  • renal failure

Endocrinologic

  • hypoglycemia (most frequent)

Fluid and Electrolyte

  • hypercalcemia (most frequent)
  • hypokalemia (most frequent)
  • hyponatremia (most frequent)
  • hypomagnesemia (most frequent)
  • hypophosphatemia (most frequent)

Hematologic

  • thrombocytopenia
  • anemia (most frequent)
  • leukopenia (most frequent)
  • lymphopenia

Musculoskeletal

  • back pain (most frequent)
  • chest wall pain (most frequent)
  • muscle spasms (most frequent)

Neurologic

  • hypoesthesia (most frequent)
  • peripheral neuropathy

Miscellaneous

  • tumor lysis syndrome (life-threatening)
  • fever/chills (most frequent)
  • infusion reactions

Interactions

Drug-Drug interaction

None noted.

Route/Dosage

Intravenous (Adults) Cycle 1—20 mg/m2 daily for 2 days weekly for 3 wk (days 1, 2, 8, 9, 15 and 16) followed by 12 day rest (days 17–28). Cycle 2 and subsequent cycles—If cycle 1 is tolerated dose should be increased to 27 mg/m2 and continued until unacceptable toxicity or disease progression. Dosa adjustments are required for hematologic, cardiac, pulmonary, renal, neurologic and hepatic toxicity.

Availability

Lyophilized powder for IV injection (requires reconstitution): 60 mg/vial

Nursing implications

Nursing assessment

  • Maintain hydration status throughout therapy. Monitor for dehydration and fluid overload.
  • Monitor for cardiac complications (new or worsening CHF, decreased left ventricular function, myocardial ischemia). Withhold dose for Grade 3 or 4 cardiac events until recovery. Consider restarting at a reduced dose. If tolerated, dose may be escalated to previous dose.
  • Assess for pulmonary hypertension with cardiac imaging. Withhold dose until resolved or returned to baseline. Consider restarting based on risk/benefit ratio. May use a reduced dose and escalate as tolerated.
  • Monitor for dyspnea frequently during therapy. Interrupt therapy until symptoms resolved; consider restarting with one dose level reduction and increase as tolerated.
  • Assess for sensory and motor peripheral neuropathy periodically during therapy. If Grade 3 or 4 occurs, withhold dose until resolved or returned to baseline. Restart with prior or reduced dose, may escalate if tolerated.
  • Lab Test Considerations: Monitor CBC and platelet count frequently during therapy. Nadir of thrombocytopenia occurs around Day 8 of 28–day cycle and recovery to baseline by start of next 28–day cycle. Withhold dose for Grade 4 thrombocytopenia or Grade 3 neutropenia. If recovered to baseline, continue with same dose. If recovered to Grade 3 thrombocytopenia or Grade 2 neutropenia, reduce dose by one dose level; may escalate if tolerated.
    • Monitor liver enzymes frequently during therapy. May cause ↑ serum transaminases and bilirubin. If Grade 3 or 4 ↑ of transaminases, bilirubin, or other liver abnormalities withhold dose until resolved or return to baseline. May be restarted at a reduced dose with frequently liver function monitoring; may escalate dose if tolerated.
    • Monitor renal function frequently during therapy. If serum creatinine ≥2 times baseline, withhold dose until recovered to Grade 1 or to baseline. If renal function decline in attributed to therapy restart at a reduced dose; if not restart at prior dose. May escalate dose if tolerated.
    • May cause hyperglycemia, hypercalcemia, hypophosphatemia, and hyponatremia.

Potential Nursing Diagnoses

Activity intolerance

Implementation

  • Hydrate patient to reduce risk of renal toxicity and tumor lysis syndrome. Prior to each dose administer 250–500 mL IV of 0.9% NaCl or other appropriate fluid. Administer another 250–500 mL as needed following therapy.
    • Premedicate with dexamethasone 4 mg PO or IV prior to all doses of Cycle 1 and prior to all doses during first cycle of dose escalation. Reinstate if symptoms develop during subsequent cycles.
  • Intravenous Administration
  • Intermittent Infusion: Reconstitute each vial by injecting 29 mL Sterile Water for injection directed onto inside wall of vial to minimize foaming. Swirl gently or invert slowly for 1 min or until complete dissolution of powder; do not shale. If foaming occurs, allow solution to rest for 2–5 min until foaming subsides. Solution should be clear and colorless; do not administer solutions that are discolored or contain particulate matter. Diluent: Withdraw calculated dose from vial and dilute in 50 mL D5W. Vial may exceed required dose; calculate dose carefully to prevent overdosing. Reconstituted solution is stable at room temperature for 4 hrs and 24 hrs if refrigerated. Discard unused portion.
  • Rate: Infuse over 2–10 min; do not administer as a bolus. Flush line with 0.9% NaCl or D5W prior to and following administration.
  • Y-Site Incompatibility: Do not mix with or infuse with other medications.

Patient/Family Teaching

  • Explain purpose of medication to patient.
  • Advise patient to notify health care professional if infusion reactions (fever, chills, rigors, arthralgia, myalgia, facial flushing, facial edema, vomiting, weakness, shortness of breath, hypotension, syncope, chest tightness, chest pain, cough, swelling of feet or legs) occur. May occur immediately or up to 24 hrs after administration.
  • May cause fatigue, dizziness, fainting, and drop in BP. Caution patient to avoid driving or other activities requiring alertness until response to medication is known.
  • Advise patient to maintain hydration status during therapy.
  • Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
  • Advise female patients to use effective contraception during therapy and to avoid breastfeeding.

Evaluation/Desired Outcomes

  • Slowed progression of multiple myeloma.
References in periodicals archive ?
- The Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion to Thousand Oaks, California-based human therapeutics developer Amgen (NASDAQ: AMGN) recommending a label variation for Kyprolis (carfilzomib) to include the final overall survival (OS) data from the Phase 3 ASPIRE trial, the company said.
The Scottish Medicines Consortium (SMC) has announced that multiple myeloma patients in Scotland will soon have access to Amgen's (NASDAQ: AMGN) Kyprolis (carfilzomib), PM Live reported on Wednesday.
Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) to expand the Prescribing Information for KYPROLIS (carfilzomib) to include a once-weekly dosing option in combination with dexamethasone (once-weekly Kd70) for patients with relapsed or refractory multiple myeloma.
M2 PHARMA-February 2, 2018-CHMP Allows Amgen to Add Overall Survival Data to Kyprolis (carfilzomib) Label
In its Final Appraisal Determination (FAD), the National Institute for Health and Care Excellence (NICE) has recommended Amgen's (NASDAQ: AMGN) Kyprolis (carfilzomib) in combination with dexamethasone as an option for treating adults with relapsed multiple myeloma (RMM) who have received one previous therapy, not including bortezomib, the company disclosed on Tuesday.
Contract notice: Supply of exclusive medicines: Carfilzomib 60 mg, 1 vial
According to PM Live, the results demonstrated that relapsed myeloma patients who were treated with Kyprolis (carfilzomib) lived more than seven months longer than those on Velcade (bortezomib).
- US-based Adaptive Biotechnologies, a specialist in combining sequencing and bioinformatics to profile T- and B-cell receptors of the adaptive immune system, has entered into a collaboration agreement with US-based biotechnology company Amgen to utilise Adaptive's NGS-based clonoSEQ Assay in the Phase 3 CANDOR study, sponsored by Amgen in collaboration with Janssen, comparing Kyprolis (carfilzomib), Darzalex (daratumumab), and dexamethasone with Kyrpolis and dexamethasone.
It was reported on Friday that the collaboration is aimed at multiple clinical trials evaluating the combination of KYPROLIS (carfilzomib) and DARZALEX (daratumumab) in patients with multiple myeloma.
Therapeutic company Amgen (NasdaqGS:AMGN) said on Friday that it has submitted a variation of its Marketing Authorization Application (MAA) to expand the indication for Kyprolis (carfilzomib) in combination with dexamethasone for treating multiple myeloma, an incurable blood cancer, characterised by a recurring pattern of remission and relapse.
In conjunction, Selinexor and low dose dexamethasone is already being combined with carfilzomib (Kyprolis) in an Investigator Sponsored MM Trial, where promising preliminary data were presented at the American Society of Hematology (ASH) 2014 Annual Meeting.